This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of rotigotine
PDMED_ROTIGOTINE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
376 |
4. Check minimum number of events
Min. number of events
3
|
376 |
5. Include endpointsNone |
376 |
6. Filter based on genotype QC (FinnGen only) |
376 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Use of rotigotine
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 376 | 212 | 164 |
| Unadjusted period prevalence (%) | 0.07 | 0.07 | 0.07 |
| Median age at first event (years) | 64.25 | 63.53 | 65.18 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 323
- Matched controls
- 3228
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BC09
ATC
rotigotine; transdermal
+∞
323.0
323
*
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
359.1
277.6
250
30
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
303.8
277.4
255
39
G20
ICD-10 Finland
Parkinson disease
303.7
271.3
249
35
N04BD01
ATC
selegiline; oral
415.3
209.3
190
11
N04BC04
ATC
ropinirole; oral
348.3
190.3
176
11
N04BC05
ATC
pramipexole; oral
55.3
181.9
228
134
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
446.1
174.3
160
7
N04BD02
ATC
rasagiline; oral
271.0
155.3
148
10
193
Kela drug reimbursment
Rasagiline
312.8
137.7
131
7
N87
ICPC
Parkinsonism
129.7
123.4
127
16
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
558.0
49.8
48
*
N03AE01
ATC
clonazepam; systemic
12.8
49.8
94
100
N04BX02
ATC
entacapone; oral
120.3
39.8
42
*
N04BB01
ATC
amantadine; oral
30.5
33.9
45
17
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
130.4
33.4
35
*
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
122.1
31.3
33
*
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
36.7
30.8
39
12
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
18.8
30.4
47
29
R25.1
ICD-10 Finland
Tremor, unspecified
16.4
29.5
48
34
N03AX12
ATC
gabapentin; oral
4.8
27.7
108
305
AA1AD
NOMESCO Finland
CT of head and brain
4.0
27.2
140
515
N04AA02
ATC
biperiden; systemic
18.4
27.1
42
26
N06DA03
ATC
rivastigmine; oral, transdermal
10.0
23.0
47
54
N05AH04
ATC
quetiapine; oral
4.3
22.6
97
294
G04BD12
ATC
mirabegron; oral
5.0
21.5
76
188
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
82.4
21.0
23
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.2
20.8
89
266
XA800
NOMESCO Finland
Neuropsychological investigation
9.1
19.2
41
51
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.4
18.5
59
129
ZXM20
NOMESCO Finland
Intraoperative use of computerised tomography
47.0
18.5
22
5
L28
ICPC
Limited function/disability (L)
3.7
18.3
95
330
N06AX11
ATC
mirtazapine; oral
3.0
18.1
149
725
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
3.0
17.8
141
667
SPAT1231
SPAT
Assessment of adjustments needed in living environment
14.4
17.3
29
22
C07AA05
ATC
propranolol; systemic
3.3
16.8
101
392
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.3
16.7
53
115
SPAT1229
SPAT
Assessment of need for aid
4.6
16.4
60
152
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
5.1
15.5
51
115
N03AX16
ATC
pregabalin; oral
2.9
14.9
114
515
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
8.1
14.3
32
43
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.6
13.9
50
124
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.0
13.5
88
354
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
4.5
13.4
49
123
R53
ICD-10 Finland
Malaise and fatigue
2.8
13.2
100
441
R47.1
ICD-10 Finland
Dysarthria and anarthria
23.7
13.0
18
8
N19
ICPC
Speech disorder
18.2
12.7
19
11
A28
ICPC
Limited function/disability NOS
3.1
12.6
78
303
Q79.6
ICD-10 Finland
Ehlers-Danlos syndrome
135.0
12.5
13
*
G93.3
ICD-10 Finland
Postviral fatigue syndrome
135.0
12.5
13
*
R1250
NOMESCO Finland
Evaluation of functional capability
11.2
12.5
23
22
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.2
12.3
38
80
K59.09
ICD-10 Finland
Constipation, unspecified
4.5
12.0
43
106
M48.0
ICD-10 Finland
Spinal stenosis
3.2
11.1
65
239
N06AX21
ATC
duloxetine; oral
3.3
11.0
60
210
N04BC06
ATC
cabergoline; oral (dopamine agonists)
44.9
11.0
13
*
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
12.5
11.0
19
16
M79.6
ICD-10 Finland
Pain in limb
2.3
10.8
140
810
YX8AD
NOMESCO Finland
Stereotactic CT examination for dose design of radiotherapy
+∞
10.5
10
*
N04BC07
ATC
apomorphine; parenteral
+∞
10.5
10
*
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
4.2
10.4
40
106
M03BX01
ATC
baclofen; systemic
12.7
10.0
17
14
R4130
NOMESCO Finland
Speech therapy
8.8
9.7
20
24
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.6
9.6
76
338
N28
ICPC
Limited function/disability (N)
9.1
9.4
19
22
F02.39
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
+∞
9.4
9
*
M01AH05
ATC
etoricoxib; oral
2.1
9.4
205
1463
H02AA02
ATC
fludrocortisone; oral
16.2
9.1
14
9
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
7.8
9.1
20
27
D21
ICPC
Swallowing problem
11.2
8.9
16
15
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.5
8.5
39
121
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.8
8.4
27
60
R35
ICD-10 Finland
Polyuria
3.7
8.3
36
106
L03
ICPC
Low back symptom/complaint
2.2
8.3
94
500
L86
ICPC
Back syndrome with radiating pain
4.1
8.2
31
81
M54.5
ICD-10 Finland
Low back pain
2.1
8.2
116
679
I95.1
ICD-10 Finland
Orthostatic hypotension
5.0
8.1
25
53
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.0
7.9
46
170
R13
ICD-10 Finland
Dysphagia
3.3
7.8
39
129
M35.7
ICD-10 Finland
Hypermobility syndrome
15.5
7.8
12
8
N06AX16
ATC
venlafaxine; oral
2.6
7.7
58
250
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
25.7
7.6
10
*
M03BC01
ATC
orphenadrine (citrate); systemic
2.2
7.5
89
481
N05BA04
ATC
oxazepam; oral
2.1
7.5
97
543
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.0
7.5
110
651
WX002
NOMESCO Finland
Sedation and analgesia
2.2
7.5
81
420
L17
ICPC
Foot/toe symptom/complaint
2.1
7.5
100
567
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
3.0
7.3
41
147
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
7.6
7.3
16
22
SPAT1216
SPAT
Assessment of functional ability
2.4
7.2
67
323
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.7
7.1
30
87
XXA00
NOMESCO Finland
Clinical examination requiring general anaesthesia
14.2
6.9
11
8
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
3.7
6.9
29
84
N02BE01
ATC
paracetamol; systemic, rectal
2.4
6.7
286
2472
N29
ICPC
Neurological sympt/complt other
5.7
6.7
18
33
H50.52
ICD-10 Finland
Exophoria
23.1
6.7
9
*
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
23.1
6.7
9
*
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.4
6.7
59
276
U04
ICPC
Incontinence urine
4.0
6.6
25
66
N06AB10
ATC
escitalopram; oral
2.2
6.6
71
363
SPAT1301
SPAT
No procedures
1.9
6.5
118
749
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
8.4
6.4
13
16
N02AX02
ATC
tramadol; systemic, rectal
1.8
6.4
147
1012
AAW01
NOMESCO Finland
Implantation of intracranial stimulation device
+∞
6.3
6
*
N04BC02
ATC
pergolide; oral
+∞
6.3
6
*
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
3.8
6.3
25
70
WX290
NOMESCO Finland
Other blockade of nerve
1.8
6.2
132
881
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.2
6.2
65
329
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.5
6.2
51
228
A02BC03
ATC
lansoprazole; oral
1.9
6.1
112
710
XF606
NOMESCO Finland
Ortostatic test
12.8
6.1
10
8
X59
ICD-10 Finland
Exposure to unspecified factor
2.2
6.1
64
325
WX402
NOMESCO Finland
General anaesthesia
2.2
6.1
62
311
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
6.2
6.1
15
25
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.2
6.0
64
327
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
301
2112
3.13
18.26
6.8
4.5
8988.33
2143.74
e6/l
—
6
38
278
1895
2.79
17.33
5.3
4.7
6.29
6.72
mmol/l
4.99
267
1776
250
1619
2.62
17.29
6.8
6.5
1.21
1.22
mmol/l
0.71
208
1372
234
1490
2.51
16.43
6.6
5.6
1.20
1.22
mmol/l
1.91
215
1348
177
997
2.46
16.24
2.6
2.1
227.74
172.25
u/l
0.35
171
931
198
1174
2.45
16.20
3.8
3.1
—
—
—
0
0
133
693
2.42
14.10
1.8
1.7
390.01
453.11
pmol/l
2.06
113
563
125
638
2.44
13.83
1.8
1.7
1409.02
1260.56
nmol/l
0.80
94
479
87
378
2.69
13.44
3.9
7.6
1.55
1.27
mmol/l
0.30
74
304
127
681
2.31
12.34
2.9
2.5
5.77
4.73
e6/l
0.50
115
600
228
1553
2.19
12.11
5.2
3.8
0.00
0.00
estimate
0.00
47
301
228
1566
2.16
11.68
6.7
5.0
0.00
0.00
estimate
0.00
49
301
230
1587
2.16
11.62
5.3
3.8
0.00
0.01
estimate
0.50
48
292
163
986
2.15
11.62
3.8
3.2
24.50
124.42
e6/l
0.89
129
763
209
1396
2.12
11.43
5.2
4.6
35.32
35.40
g/l
0.07
193
1304
153
910
2.15
11.33
3.7
3.0
0.24
0.42
e6/l
1.17
120
679
178
1147
2.05
10.42
4.4
3.7
131.31
101.36
e6/l
0.15
136
820
194
1305
2.01
9.92
4.6
2.6
135.48
127.62
ug/l
0.23
172
1193
135
801
2.07
9.77
1.7
1.6
19.24
20.74
nmol/l
0.61
118
671
98
523
2.18
9.29
2.3
1.9
—
—
—
0
0
77
375
2.32
9.08
2.2
1.7
—
—
—
0
0
359
3135
4.21
8.98
22.3
14.8
24.75
23.55
mg/l
0.32
309
2504
119
692
2.05
8.97
5.7
4.2
1.02
1.02
kg/l
0.57
19
92
180
1213
1.93
8.84
5.6
3.9
—
—
—
0
0
140
867
1.98
8.82
5.5
4.0
0.00
0.01
estimate
0.50
44
299
193
1334
1.92
8.75
2.4
2.0
90.30
95.22
pmol/l
0.95
112
658
48
192
2.72
8.55
1.5
1.3
—
—
—
0
0
76
378
2.27
8.50
2.3
1.8
—
—
—
0
0
95
524
2.09
8.17
2.8
1.8
28.81
29.47
s
0.76
89
504
206
1477
1.87
8.13
4.2
4.0
—
—
—
0
0
306
2508
2.18
8.08
6.7
7.7
78.04
79.48
u/l
0.26
289
2342
69
350
2.19
7.30
5.4
3.4
—
—
—
0
0
183
1296
1.80
7.23
4.2
3.8
33.17
58.54
ng/l
0.46
143
950
294
2427
1.97
6.84
4.1
3.9
15.14
14.90
pmol/l
0.72
261
2172
364
3292
4.31
6.84
26.0
17.1
139.81
139.69
mmol/l
0.47
356
3207
95
559
1.94
6.69
3.2
2.7
2.70
1.04
e6/l
0.53
54
312
364
3303
4.20
6.56
26.3
17.2
3.95
3.98
mmol/l
1.25
356
3215
118
772
1.77
5.83
2.8
2.1
3.14
3.31
mg/l
0.22
93
664
43
197
2.34
5.77
2.3
1.6
—
—
—
0
0
80
469
1.90
5.62
4.7
2.2
2.20
2.35
g/l
1.45
71
435
154
1108
1.66
5.28
2.7
3.4
2.33
2.36
mmol/l
1.59
138
969
19
59
3.34
5.24
3.9
2.6
16.41
15.98
%
—
10
25
85
520
1.82
5.20
4.5
2.2
13.77
12.80
umol/l
0.50
75
480
56
303
2.00
4.95
2.2
1.8
398.51
379.56
nmol/l
0.30
51
282
144
1032
1.64
4.94
3.2
3.2
28.20
31.66
u/l
0.51
134
982
96
619
1.74
4.89
4.6
3.7
77.54
209.95
ng/l
1.57
74
511
367
3463
3.50
4.74
31.9
21.8
4.33
4.47
e12/l
5.79
359
3365
367
3464
3.48
4.74
32.1
21.9
130.48
135.13
g/l
7.41
361
3410
45
228
2.11
4.74
1.3
1.6
—
—
—
0
0
367
3462
3.51
4.74
31.8
21.8
246.49
246.94
e9/l
0.05
359
3374
280
2384
1.68
4.60
4.2
4.2
12.72
12.34
mm/h
0.13
253
2195
328
2923
1.96
4.60
5.1
4.7
1.93
2.34
mu/l
0.49
299
2650
74
455
1.78
4.41
5.0
2.2
23.82
21.77
%
0.60
60
390
141
1028
1.59
4.41
2.6
3.1
1179.40
1118.44
ng/l
0.08
116
873
82
521
1.73
4.36
3.4
3.0
3.19
2.39
e6/l
0.24
41
282
47
252
1.99
4.26
2.2
3.3
147.40
185.27
ng/l
0.40
40
230
50
278
1.92
4.09
2.9
3.9
1.21
1.23
mmol/l
1.21
42
240
169
1316
1.52
3.80
2.6
2.2
76.27
77.79
nmol/l
0.32
151
1158
14
46
3.12
3.56
1.6
1.3
111.93
105.00
u/ml
—
7
10
211
1745
1.48
3.40
4.3
6.3
10.45
11.31
umol/l
1.13
197
1648
137
1044
1.49
3.31
2.3
2.4
56.85
56.57
u/l
0.02
124
962
18
72
2.58
3.26
1.6
1.3
3.50
8.96
e6/l
0.60
12
55
9
20
4.58
3.13
1.4
1.6
—
—
—
0
0
63
411
1.64
3.01
6.4
7.6
—
—
—
0
0
89
631
1.54
3.00
2.8
3.0
2.43
2.46
mmol/l
2.61
78
559
209
1756
1.43
2.91
2.8
2.7
—
—
—
0
0
48
296
1.71
2.83
5.8
3.3
3.16
2.10
mmol/l
1.44
37
237
14
53
2.70
2.82
1.2
1.2
—
—
—
0
0
5
6
8.42
2.75
1.0
1.2
—
—
—
0
0
102
761
1.47
2.67
2.6
2.3
—
—
—
0
0
26
136
1.98
2.57
1.7
2.0
1.41
4.34
ug/l
0.70
21
121
94
703
1.45
2.41
2.2
1.6
0.89
1.29
mg/l
1.82
80
548
7
17
4.17
2.37
2.3
2.1
—
—
—
0
0
286
2590
1.44
2.33
27.9
17.9
13.60
13.73
%
0.86
279
2545
8
23
3.53
2.28
1.6
2.0
—
—
—
0
0
18
87
2.12
2.21
1.7
1.3
32.64
29.31
iu/l
0.16
18
73
46
302
1.60
2.16
3.2
2.4
43.38
32.86
u/l
0.34
39
249
7
19
3.73
2.16
1.7
2.1
—
—
—
0
0
353
3359
1.83
2.14
10.8
11.0
18.41
25.63
u/l
21.12
333
3233
33
199
1.72
2.14
1.2
1.3
—
51.05
—
0
13
7
20
3.55
2.06
1.7
2.0
—
—
—
0
0
175
1487
1.33
2.01
5.3
5.7
60.24
57.60
%
2.59
162
1393
212
1855
1.33
1.97
6.7
9.2
4.26
4.12
e9/l
0.37
189
1633
17
86
2.02
1.88
1.5
1.8
—
—
—
0
0
176
1512
1.31
1.82
5.4
6.0
25.03
27.48
%
2.41
162
1407
22
127
1.78
1.68
1.9
1.6
2.82
3.20
g/l
1.24
17
104
11
49
2.28
1.65
1.4
1.8
—
—
—
0
0
5
14
3.60
1.62
1.4
3.7
—
—
—
0
0
5
14
3.60
1.62
1.4
3.7
—
—
—
0
0
14
70
2.04
1.61
3.2
2.5
8.76
7.94
kpa
1.21
14
63
18
101
1.82
1.51
1.4
1.4
255.13
279.89
ug/g
0.20
12
63
15
79
1.94
1.51
1.2
1.7
—
—
—
0
0
13
65
2.04
1.50
1.2
1.6
—
—
—
0
0
9
38
2.40
1.46
1.1
1.1
—
—
—
0
0
7
28
2.53
1.46
1.6
2.0
—
—
—
0
0
14
73
1.95
1.45
1.1
1.1
—
—
—
0
0
13
237
0.53
1.44
2.0
1.9
—
—
—
0
0
16
88
1.85
1.43
2.2
1.4
—
—
—
0
0
22
136
1.66
1.36
1.9
1.6
3.54
3.75
g/l
0.41
17
102
22
136
1.66
1.36
1.9
1.6
—
—
—
0
0
22
136
1.66
1.36
1.9
1.6
7.15
7.64
g/l
0.51
16
108
41
294
1.44
1.33
2.6
2.5
6.88
6.19
ug/l
0.11
34
264
299
2811
1.31
1.32
25.5
15.6
37.91
39.57
%
1.51
165
1923
12
62
1.97
1.29
1.9
1.3
—
—
—
0
0
12
62
1.97
1.29
1.9
1.3
—
—
—
0
0
14
77
1.85
1.27
1.6
1.6
—
—
—
0
0
225
2056
1.23
1.21
3.2
3.2
38.79
51.70
u/l
1.42
201
1903
8
38
2.13
1.19
1.5
1.9
—
—
—
0
0
48
364
1.37
1.16
3.2
2.8
6.57
8.53
umol/l
0.34
43
322
18
111
1.65
1.14
2.3
2.0
209.21
264.73
ug/l
0.27
18
102
89
1052
0.80
1.07
4.2
3.9
20.17
7.84
mg/mmol
0.75
60
641
16
98
1.66
1.05
1.3
1.2
—
—
—
0
0
80
663
1.26
1.04
1.2
1.2
1.79
1.64
u/ml
0.06
16
182
7
34
2.08
1.03
1.0
1.2
—
—
—
0
0
10
53
1.91
1.02
1.5
2.7
104.80
105.91
mmol/l
—
10
53
17
107
1.62
1.01
2.1
1.6
0.00
0.05
g/l
0.50
17
100
17
107
1.62
1.01
1.5
1.7
—
216.67
—
0
6
289
3029
0.80
1.00
3.7
4.2
1.15
1.28
mmol/l
3.18
251
2755
67
548
1.27
0.97
1.3
1.3
34.17
42.49
iu/ml
0.27
20
168
15
93
1.64
0.95
1.1
1.2
—
—
—
0
0
9
51
1.78
0.95
1.0
1.1
—
—
—
0
0
16
101
1.61
0.95
2.2
1.6
0.00
0.00
g/l
0.00
16
95
54
431
1.30
0.94
15.2
20.4
1.44
1.34
inr
—
7
53
12
70
1.74
0.93
1.3
1.3
—
—
—
0
0
16
102
1.59
0.92
2.2
1.6
0.00
0.00
g/l
0.00
16
95
15
94
1.62
0.92
1.1
1.2
—
—
—
0
0
12
71
1.71
0.90
2.1
1.5
—
—
—
0
0
6
29
2.09
0.89
1.0
1.2
—
—
—
0
0
301
3128
0.81
0.85
4.3
4.6
1.47
1.48
mmol/l
0.07
269
2860
15
97
1.57
0.82
1.8
1.7
—
—
—
0
0
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
8
48
1.68
0.79
1.6
1.9
—
—
—
0
0
0
28
0.00
0.76
0.0
1.5
—
—
—
0
0
103
906
1.19
0.76
4.6
4.3
22.74
20.74
%
0.67
53
443
9
53
1.71
0.76
1.2
3.5
54.78
59.40
%
—
9
53
11
67
1.66
0.76
2.7
1.2
—
—
—
0
0
9
55
1.65
0.74
1.4
2.2
—
—
—
0
0
5
27
1.86
0.68
1.0
1.2
—
68.00
—
0
5
25
188
1.35
0.68
1.4
1.2
66.46
119.63
iu/ml
—
5
74
323
3130
1.23
0.68
4.5
4.8
5.90
6.00
mmol/l
0.72
285
2857
5
91
0.54
0.68
1.2
1.3
—
—
—
0
0
310
2995
1.20
0.65
19.4
13.7
84.05
78.33
ml/min/173m2
4.43
273
2476
37
451
0.80
0.60
1.4
1.4
—
—
—
0
0
306
3150
0.85
0.58
4.3
4.7
4.57
4.64
mmol/l
0.46
274
2899
8
54
1.49
0.57
1.6
1.7
—
—
—
0
0
6
36
1.68
0.57
1.0
1.1
—
—
—
0
0
8
55
1.46
0.56
1.6
1.8
—
—
—
0
0
6
37
1.63
0.56
1.8
1.5
—
—
—
0
0
96
862
1.15
0.55
2.0
2.7
328.10
8850.47
umol/l
4.42
82
724
6
38
1.59
0.54
1.0
1.1
—
—
—
0
0
11
75
1.48
0.51
1.3
1.2
—
—
—
0
0
11
155
0.70
0.49
1.1
1.0
—
—
—
0
0
11
76
1.46
0.48
1.4
2.0
—
—
—
0
0
11
76
1.46
0.48
1.4
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
2.8
—
—
—
0
0
0
15
0.00
0.41
0.0
2.8
—
—
—
0
0
0
15
0.00
0.41
0.0
2.8
—
—
—
0
0
0
15
0.00
0.41
0.0
2.8
—
—
—
0
0
18
141
1.29
0.41
1.1
1.3
—
—
—
0
0
31
260
1.21
0.41
3.4
2.7
82.13
60.17
ml/min/173m2
—
8
112
0
17
0.00
0.40
0.0
2.2
—
47.83
—
0
12
315
3216
0.87
0.40
4.8
5.3
2.68
2.72
mmol/l
0.29
282
2941
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
106
1.33
0.39
7.6
2.2
0.28
0.37
u/ml
—
6
59
5
35
1.43
0.39
2.8
1.6
—
—
—
0
0
37
428
0.85
0.38
3.4
4.6
35.16
31.87
%
0.78
25
282
12
89
1.36
0.38
1.2
1.4
—
—
—
0
0
59
655
0.88
0.36
3.4
3.0
0.67
0.73
ug/l
0.45
41
446
5
78
0.64
0.36
1.2
1.4
—
—
—
0
0
14
108
1.31
0.36
2.1
3.4
—
2.46
—
0
13
6
43
1.40
0.35
1.8
1.3
—
—
—
0
0
10
75
1.34
0.30
1.2
1.2
—
0.96
—
0
5
119
1125
1.08
0.28
4.7
4.9
1.92
2.34
ug/l
0.69
110
1001
8
65
1.24
0.27
1.6
1.7
—
—
—
0
0
85
906
0.92
0.25
1.7
1.7
1.33
1.35
mmol/l
0.08
71
755
58
534
1.10
0.24
1.4
1.3
1.47
14.16
u/ml
3.39
24
205
0
11
0.00
0.21
0.0
1.0
—
9.38
—
0
11
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
454.33
—
0
6
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
5
43
1.16
0.21
1.2
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
13
110
1.19
0.17
1.3
1.9
—
—
—
0
0
8
72
1.11
0.16
1.1
1.3
—
38.20
—
0
7
9
108
0.83
0.13
1.6
1.2
1.25
1.20
g/l
—
9
103
304
3008
1.06
0.13
6.2
6.1
39.51
40.06
mmol/mol
0.53
274
2787
10
85
1.18
0.12
1.1
1.4
—
—
—
0
0
35
374
0.93
0.12
2.9
4.1
2.33
42.70
ug/l
1.19
28
318
14
124
1.13
0.11
1.7
1.9
—
—
—
0
0
5
44
1.14
0.10
1.0
1.1
—
25.78
—
0
9
5
48
1.04
0.09
1.0
1.0
—
—
—
0
0
11
97
1.14
0.09
1.2
1.3
—
2.13
—
0
6
13
117
1.12
0.08
1.6
1.7
—
—
—
0
0
6
70
0.85
0.07
1.3
1.2
—
11.84
—
0
9
9
102
0.88
0.06
1.4
1.2
0.25
0.24
g/l
—
9
97
10
91
1.10
0.04
1.2
1.3
—
2.67
—
0
16
10
92
1.09
0.03
1.2
1.3
—
7.64
—
0
19
11
117
0.94
0.02
1.5
3.1
—
—
—
0
0
19
183
1.04
0.01
1.6
1.9
—
—
—
0
0
16
165
0.97
0.00
1.6
1.8
—
—
—
0
0
43
435
0.99
0.00
1.3
1.4
—
—
—
0
0
5
59
0.85
0.00
2.2
3.2
12.80
29.17
u/ml
—
5
59
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
2.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
5
51
0.98
0.00
3.6
3.1
—
725.29
—
0
7
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
77.50
—
0
6
0
5
0.00
0.00
0.0
1.0
—
14.66
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
9
93
0.97
0.00
1.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_ROTIGOTINE – Use of rotigotine
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).